On­colyt­ic virus play­er Replimune sees progress on lead pro­gram, but fol­low-up can­di­date's ef­fec­tive­ness re­mains in­con­clu­sive

On­colyt­ic virus biotech Replimune put out a com­pre­hen­sive pipeline up­date Wednes­day morn­ing, in­di­cat­ing its lead pro­gram re­mains on its de­vel­op­ment track. But ques­tions lin­gered re­gard­ing a fol­low-up can­di­date in­tend­ed to treat some of the sick­est can­cer pa­tients.

Replimune’s lead can­di­date, known as RP1, in­creased its over­all re­sponse rate in a va­ri­ety of can­cer pop­u­la­tions, in­clud­ing skin can­cer pa­tients who had and had not been treat­ed with a PD-1. The fol­low-up pro­gram, called RP3, has yet to in­duce any re­spons­es, how­ev­er, af­ter be­ing used to treat a small num­ber of very sick pa­tients.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER